The data presented here builds on existing work and shows that elevated SEMA3C levels in FOXA1-alterated prostate cancer patients may be linked to intronic FOXA1 elements in SEMA3C. We note that the FOXA1 motif in the second intron of SEMA3C overlaps with the ARE (Fig. 4) which we previously determined to confer positive AR regulation of SEMA3C. It is therefore possible that FOXA1 normally co-occupies this ARE or displaces AR from this region with the net effect of dampened SEMA3C expression. The gene discussed is FOXA1; the disease is prostate cancer.